Aprotinin
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Aprotinin: Repurposing Evaluation — Insufficient Data for Standard Assessment
One-Sentence Summary
Aprotinin (DrugBank: DB06692) is a serine protease inhibitor with a history of use as an antifibrinolytic agent in cardiac surgery, but it carries no current SAHPRA registration and is not marketed in South Africa. The TxGNN prediction pipeline returned no repurposing candidates for this drug in the current evidence pack, and critical data — including mechanism of action, safety warnings, and contraindications — remain unresolved. No repurposing recommendation can be issued at this time; this report serves as a structured gap analysis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no SAHPRA registrations on record) |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | Not available |
| Evidence Level | Not applicable — no predictions generated |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
Because the TxGNN model returned an empty prediction list for aprotinin, a mechanistic rationale for any new indication cannot be formally evaluated. Two contributing factors are likely:
1. Missing mechanism of action data. The evidence pack flags MOA as an unresolved gap (DG002). TxGNN relies on drug–target–disease relationships within the knowledge graph; if aprotinin’s pharmacological targets are not adequately represented or linked, the model may fail to generate confident repurposing scores.
2. No local regulatory anchor. With zero SAHPRA registrations and no approved indication text, the pipeline lacks the local regulatory context that would normally anchor a South African repurposing assessment.
From publicly available sources, aprotinin is a broad-spectrum serine protease inhibitor (bovine pancreatic trypsin inhibitor, BPTI). It inhibits plasmin, kallikrein, and trypsin, reducing fibrinolysis and perioperative blood loss. It was previously marketed as Trasylol® (Bayer) for reduction of haemorrhage during cardiac surgery. Global market suspension occurred in 2008 following the BART trial, which identified excess all-cause mortality and serious renal and cardiovascular events compared with lysine analogues (tranexamic acid, aminocaproic acid). A restricted re-approval has since been granted in certain jurisdictions (e.g., Canada, Europe) with mandatory risk-minimisation measures. This historical safety context is material to any future repurposing consideration and must be explicitly addressed before any pipeline re-run.
South Africa Market Information
Aprotinin is not currently registered with SAHPRA and has no approved products on the South African market. No Essential Medicines List (EML) inclusion applies. Before any repurposing pathway could be pursued, a full SAHPRA submission — or at minimum a Section 21 authorisation for restricted investigational use — would be required.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Important historical safety signal: Aprotinin was subject to a global market suspension in 2008 following the BART trial (NCT00182585), which demonstrated a statistically significant increase in 30-day all-cause mortality compared with tranexamic acid and aminocaproic acid. Serious adverse events included acute renal failure, myocardial infarction, and stroke. Any consideration of use or repurposing in a South African setting must account for this risk profile and the restricted conditions under which re-approval has been granted elsewhere.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence pack is structurally incomplete — TxGNN generated no predictions, SAHPRA registration is absent, and both mechanism-of-action and safety data remain unresolved. There is no evidential basis on which to proceed with a repurposing evaluation under the current framework.
To proceed, the following is needed:
- Resolve DG002 (High): Retrieve full pharmacological target and MOA data from DrugBank API for DB06692 and confirm knowledge graph coverage before re-running TxGNN
- Resolve DG001 (Blocking): Obtain an equivalent regulatory document (e.g., EMA or Health Canada SmPC/Product Monograph) to substitute for the missing SAHPRA PI; extract warnings, contraindications, and special population restrictions
- Re-run the TxGNN prediction pipeline after data gaps are remediated to determine whether any repurposing candidates are generated with sufficient confidence scores
- Conduct a structured safety review of the post-2008 re-approval conditions (Health Canada 2011, EMA 2012) to understand what risk-minimisation measures apply and whether they are feasible in the South African context
- Assess regulatory pathway: Confirm whether a SAHPRA Section 21 authorisation or a full registration submission would be required for any repurposing indication that emerges from the pipeline
- Consider alternative antifibrinolytics (tranexamic acid, which is on the South African EML) as the active comparator benchmark for any future efficacy and safety comparison
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.